|
Epilepsy
|
0.300 |
Biomarker
|
disease |
MGD |
|
|
|
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The first pattern, detected in 25 of 35 SMS patients (71%), of whom 11 had IDDM (44%), was predominantly reactive with a linear NH2-terminal epitope residing in the first eight amino acids of GAD65.
|
7519242 |
1994 |
|
Stiff-Person Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, destruction of pancreatic beta cells, which results in insulin-dependent diabetes mellitus (IDDM), and impairment of GABA-ergic synaptic transmission in Stiff-Man syndrome (SMS) are both characterized by circulating autoantibodies to GAD65.
|
7519242 |
1994 |
|
Smith-Magenis syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, destruction of pancreatic beta cells, which results in insulin-dependent diabetes mellitus (IDDM), and impairment of GABA-ergic synaptic transmission in Stiff-Man syndrome (SMS) are both characterized by circulating autoantibodies to GAD65.
|
7519242 |
1994 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The findings suggest that none of the single antibody specificities are as sensitive as islet cell antibodies, but that a combination of GAD65 antibodies and antibodies to 37,000/40,000 M(r) islet tryptic fragments has the potential to identify more than 90% of future cases of IDDM.(ABSTRACT TRUNCATED AT 250 WORDS)
|
7556984 |
1995 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The clinical onset of insulin-dependent diabetes is associated with several autoimmune phenomena including islet cell antibodies, glutamic acid decarboxylase (the GAD65 isoform) autoantibodies (GAD65Ab) as well as insulin autoantibodies.
|
7821743 |
1994 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The titer of GAD65 autoantibodies was much higher in the restricted ICA sera (titer > 1:1,000) than in the sera from individuals with new-onset diabetes or prediabetes (titer < 1:100) and was reflected by the greater amount of GAD65 protein immunoprecipitated by restricted ICA sera (2.61 +/- 1.39 U) compared with sera from individuals with new-onset diabetes (0.51 +/- 0.34 U).
|
8039604 |
1994 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The titer of GAD65 autoantibodies was much higher in the restricted ICA sera (titer > 1:1,000) than in the sera from individuals with new-onset diabetes or prediabetes (titer < 1:100) and was reflected by the greater amount of GAD65 protein immunoprecipitated by restricted ICA sera (2.61 +/- 1.39 U) compared with sera from individuals with new-onset diabetes (0.51 +/- 0.34 U).
|
8039604 |
1994 |
|
Prediabetes syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
The titer of GAD65 autoantibodies was much higher in the restricted ICA sera (titer > 1:1,000) than in the sera from individuals with new-onset diabetes or prediabetes (titer < 1:100) and was reflected by the greater amount of GAD65 protein immunoprecipitated by restricted ICA sera (2.61 +/- 1.39 U) compared with sera from individuals with new-onset diabetes (0.51 +/- 0.34 U).
|
8039604 |
1994 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
In competition analysis with unlabeled purified recombinant human islet GAD65, binding to tracer was inhibited in 74% (74 of 100) of the GAD65-positive IDDM serum samples compared with 2% of the control samples.
|
8314020 |
1994 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay.
|
8314020 |
1994 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay.
|
8314020 |
1994 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay.
|
8314020 |
1994 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The practicability of using recombinant GAD65 and GAD67 derived from the baculovirus expression system for the development of an immunoassay for the diagnosis of insulin-dependent diabetes mellitus is discussed.
|
8370667 |
1993 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type.
|
8423232 |
1993 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type.
|
8423232 |
1993 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The data illustrate that antibodies against GAD-65 are present in a majority of patients with type 1 diabetes mellitus and that autoantibodies against other islet cell antigens also exist.
|
8486775 |
1993 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
In vitro stimulation with glutamic acid decarboxylase (GAD65) leads to an oligoclonal response of peripheral T-cells in an IDDM patient.
|
8552991 |
1995 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
To determine whether variation in the GAD65 gene plays a role in genetic susceptibility to IDDM, possibly explaining the reported evidence for linkage on 10p, we isolated cosmid clones containing GAD65, and identified a highly polymorphic dinucleotide repeat physically linked to the gene.
|
8679901 |
1995 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
At the same time, the molecular cloning of human islet GAD65 and the development of precise and reproducible GAD65Ab assays with recombinant human GAD65 has given new insights to the problem of to what extent HLA control the development of a GAD65 immune response or to the development of IDDM.Recent data are briefly reviewed.
|
8689840 |
1996 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Tests for the detection of autoantibodies to recombinant IA-2 and GAD65 may eventually replace ICA immunofluorescence for IDDM population screening.
|
8692821 |
1996 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The results suggest that, in humans, an antigen driven B cell activation and affinity maturation process may contribute to the production of GAD65-autoantibodies found in patients with IDDM.
|
8816973 |
1996 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
In conclusion, T cell clones to specific epitopes of GAD 65 provide a model to clarify those differences in the immune response to this autoantigen between controls and IDDM patients.
|
8816975 |
1996 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Rat GAD65 was expressed as a fusion protein in the expression vector RSET and inhibited ICA (GAD+ICA) in 26% of 23 recent onset patients, 29% of 14 ICA positive first degree relatives (FDR) who progressed to diabetes (prediabetics) and 50% of 20 FDR who did not progress to diabetes 18 months to 5 years (31 +/- 14 months) after collection of the sample.
|
8824714 |
1995 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Rat GAD65 was expressed as a fusion protein in the expression vector RSET and inhibited ICA (GAD+ICA) in 26% of 23 recent onset patients, 29% of 14 ICA positive first degree relatives (FDR) who progressed to diabetes (prediabetics) and 50% of 20 FDR who did not progress to diabetes 18 months to 5 years (31 +/- 14 months) after collection of the sample.
|
8824714 |
1995 |